JP2025520692A5 - - Google Patents

Info

Publication number
JP2025520692A5
JP2025520692A5 JP2024575463A JP2024575463A JP2025520692A5 JP 2025520692 A5 JP2025520692 A5 JP 2025520692A5 JP 2024575463 A JP2024575463 A JP 2024575463A JP 2024575463 A JP2024575463 A JP 2024575463A JP 2025520692 A5 JP2025520692 A5 JP 2025520692A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
cancer
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024575463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025520692A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/101761 external-priority patent/WO2023246879A1/en
Publication of JP2025520692A publication Critical patent/JP2025520692A/ja
Publication of JP2025520692A5 publication Critical patent/JP2025520692A5/ja
Pending legal-status Critical Current

Links

JP2024575463A 2022-06-22 2023-06-21 抗ｓｌｃ３４ａ２モノクローナル抗体およびその使用 Pending JP2025520692A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/100315 2022-06-22
CN2022100315 2022-06-22
PCT/CN2023/101761 WO2023246879A1 (en) 2022-06-22 2023-06-21 Anti-slc34a2 monoclonal antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2025520692A JP2025520692A (ja) 2025-07-03
JP2025520692A5 true JP2025520692A5 (https=) 2026-04-20

Family

ID=89379184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024575463A Pending JP2025520692A (ja) 2022-06-22 2023-06-21 抗ｓｌｃ３４ａ２モノクローナル抗体およびその使用

Country Status (13)

Country Link
US (2) US12215150B2 (https=)
EP (1) EP4543926A1 (https=)
JP (1) JP2025520692A (https=)
KR (1) KR20250051643A (https=)
CN (1) CN119948054A (https=)
AU (1) AU2023289743A1 (https=)
CA (1) CA3260354A1 (https=)
CL (1) CL2024004012A1 (https=)
CO (1) CO2024017740A2 (https=)
IL (1) IL317849A (https=)
MX (1) MX2025000053A (https=)
TW (1) TW202409076A (https=)
WO (1) WO2023246879A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025131025A1 (en) * 2023-12-21 2025-06-26 Lanova Medicines Development Co., Ltd. Conjugates of anti-slc34a2 antibody and uses thereof
CN120988123B (zh) * 2025-10-21 2026-03-17 苏州近岸蛋白质科技股份有限公司 一种抗人NaPi2b的人源化单克隆抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603474B2 (en) 2008-01-29 2013-12-10 Ludwig Institute For Cancer Research, Ltd. Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Similar Documents

Publication Publication Date Title
IL302078A (en) Anti-CCR8 monoclonal antibodies and their uses
JP2022548783A5 (https=)
JP2024175003A5 (https=)
RU2013152164A (ru) Анти-в7-н3-антитело
JP2021534096A5 (https=)
JP2020500538A5 (https=)
JP2013529183A5 (https=)
JP2009545325A5 (https=)
RU2010123888A (ru) Axl-антитела
JP2020526478A5 (https=)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2022530404A5 (https=)
JP2025520692A5 (https=)
RU2009120052A (ru) Композиции и способы связывания сфингозин-1-фосфата
RU2013136172A (ru) Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
JP2017529838A5 (https=)
RU2016122041A (ru) Новые анти-клаудин антитела и способы их применения
HRP20240626T1 (hr) Bispecifična antitijela protiv ceacam5 i cd3
JP2021533159A5 (https=)
JP2024542194A5 (https=)
JP2022525377A5 (https=)
JP2021501579A5 (https=)
JP2022507253A5 (https=)
JP2025508867A5 (https=)
JP2024016024A5 (https=)